MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Decline in Short Interest

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 24,000 shares, a decrease of 17.8% from the March 15th total of 29,200 shares. Currently, 2.4% of the shares of the stock are sold short. Based on an average daily volume of 29,500 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a research note on Tuesday, March 18th.

MiNK Therapeutics Trading Up 5.7 %

Shares of NASDAQ INKT traded up $0.42 during midday trading on Tuesday, hitting $7.68. 2,008 shares of the company’s stock were exchanged, compared to its average volume of 14,584. The business’s fifty day moving average price is $8.55 and its two-hundred day moving average price is $7.85. The company has a market cap of $30.44 million, a price-to-earnings ratio of -1.97 and a beta of 0.15. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $13.79.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). Equities analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.